This study will recruit 152 HIV-infected men with alcohol use disorders (AUDs). Men will be randomized to receive either extended release-naltrexone for the treatment of alcohol use disorder or placebo. Men with acute, recent or established HIV infection will receive antiretroviral treatment (ART) and be randomized to extended release-naltrexone or placebo. The purpose of this study is to see whether use of extended release-naltrexone improves medication compliance, and therefore HIV viral load suppression, among men with alcohol use disorder. The study will also assess the impact of extended release-naltrexone on alcohol use behaviors in this population.
- Media Advisory: National Conference on Alcohol, Drugs and Other Substances in Vancouver Nov 6-9, 2011
- Jordan Valley Medical Center Expands Medical Services with the...
- Former gay football player Akil Patterson profiled
- Integrated Stepped Care for Unhealthy Alcohol Use in HIV
- RockHard Weekend and Forgiven Announce Upcoming Sponsorships and...
- Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients
- A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
- A Case Control Study of Women With Multiple Sexual Partners
- HIV Prevention Among Vulnerable Male Youth
- Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting